These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 12670639)

  • 1. Risks and benefits of rate control versus maintenance of sinus rhythm.
    Saxonhouse SJ; Curtis AB
    Am J Cardiol; 2003 Mar; 91(6A):27D-32D. PubMed ID: 12670639
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The RACE study in perspective of randomized studies on management of persistent atrial fibrillation.
    Hagens VE; Van Gelder IC; Crijns HJ;
    Card Electrophysiol Rev; 2003 Jun; 7(2):118-21. PubMed ID: 14618033
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rate versus rhythm control in patients with atrial fibrillation: what the trials really say.
    Crijns HJ
    Drugs; 2005; 65(12):1651-67. PubMed ID: 16060699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Old and new antiarrhythmic drugs for converting and maintaining sinus rhythm in atrial fibrillation: comparative efficacy and results of trials.
    Naccarelli GV; Wolbrette DL; Khan M; Bhatta L; Hynes J; Samii S; Luck J
    Am J Cardiol; 2003 Mar; 91(6A):15D-26D. PubMed ID: 12670638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Atrial fibrillation: pharmacological therapy.
    Patel C; Salahuddin M; Jones A; Patel A; Yan GX; Kowey PR
    Curr Probl Cardiol; 2011 Mar; 36(3):87-120. PubMed ID: 21392636
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atrial fibrillation: maintaining stability of sinus rhythm or ventricular rate control? The need for prospective data: the PIAF trial.
    Hohnloser SH; Kuck KH
    Pacing Clin Electrophysiol; 1997 Aug; 20(8 Pt 1):1989-92. PubMed ID: 9272538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rhythm control versus rate control in patients with persistent atrial fibrillation. Results of the HOT CAFE Polish Study.
    Opolski G; Torbicki A; Kosior D; Szulc M; Zawadzka M; Pierścińska M; Kołodziej P; Stopiński M; Wozakowska-Kapłon B; Achremczyk P; Rabczenko D
    Kardiol Pol; 2003 Jul; 59(7):1-16; discussion 15-16. PubMed ID: 14560344
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pharmacological cardioversion of atrial fibrillation: current management and treatment options.
    Boriani G; Diemberger I; Biffi M; Martignani C; Branzi A
    Drugs; 2004; 64(24):2741-62. PubMed ID: 15563247
    [TBL] [Abstract][Full Text] [Related]  

  • 9. AFFIRM and RACE trials: implications for the management of atrial fibrillation.
    Blackshear JL; Safford RE; ;
    Card Electrophysiol Rev; 2003 Dec; 7(4):366-9. PubMed ID: 15071255
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Angiotensin receptor blocker as adjunctive therapy for rhythm control in atrial fibrillation: results of the irbesartan-amiodarone trial.
    Madrid AH; Escobar C; Rebollo JM; Marín I; Bernal E; Nannini S; Limón L; Peng J; Moro C
    Card Electrophysiol Rev; 2003 Sep; 7(3):243-6. PubMed ID: 14739722
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Towards a consensus in rate versus rhythm control for management of atrial fibrillation: insights from the PIAF trial.
    Grönefeld G; Hohnloser SH
    Card Electrophysiol Rev; 2003 Jun; 7(2):113-7. PubMed ID: 14618032
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacologic management of atrial fibrillation: established and emerging options.
    Kalus JS
    J Manag Care Pharm; 2009 Aug; 15(6 Suppl B):S10-8. PubMed ID: 19678722
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Rate-control versus conversion strategy in postoperative atrial fibrillation: trial design and pilot study results.
    Lee JK; Klein GJ; Krahn AD; Yee R; Zarnke K; Simpson C; Skanes A
    Card Electrophysiol Rev; 2003 Jun; 7(2):178-84. PubMed ID: 14618047
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Systematic review of the management of atrial fibrillation in patients with heart failure.
    Khand AU; Rankin AC; Kaye GC; Cleland JG
    Eur Heart J; 2000 Apr; 21(8):614-32. PubMed ID: 10731399
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized trial of rate-control versus rhythm-control in persistent atrial fibrillation: the Strategies of Treatment of Atrial Fibrillation (STAF) study.
    Carlsson J; Miketic S; Windeler J; Cuneo A; Haun S; Micus S; Walter S; Tebbe U;
    J Am Coll Cardiol; 2003 May; 41(10):1690-6. PubMed ID: 12767648
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Functional status in rate- versus rhythm-control strategies for atrial fibrillation: results of the Atrial Fibrillation Follow-Up Investigation of Rhythm Management (AFFIRM) Functional Status Substudy.
    Chung MK; Shemanski L; Sherman DG; Greene HL; Hogan DB; Kellen JC; Kim SG; Martin LW; Rosenberg Y; Wyse DG;
    J Am Coll Cardiol; 2005 Nov; 46(10):1891-9. PubMed ID: 16286177
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rhythm or rate control in atrial fibrillation: insights from the randomized controlled trials.
    Grönefeld G; Hohnloser SH
    J Cardiovasc Pharmacol Ther; 2003 Jun; 8 Suppl 1():S39-44. PubMed ID: 12746751
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Rhythm or rate control in atrial fibrillation--Pharmacological Intervention in Atrial Fibrillation (PIAF): a randomised trial.
    Hohnloser SH; Kuck KH; Lilienthal J
    Lancet; 2000 Nov; 356(9244):1789-94. PubMed ID: 11117910
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dronedarone: a promising alternative for the management of atrial fibrillation.
    Yalta K; Turgut OO; Yilmaz MB; Yilmaz A; Tandogan I
    Cardiovasc Drugs Ther; 2009 Oct; 23(5):385-93. PubMed ID: 19669399
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety and efficacy of vernakalant for the conversion of atrial fibrillation to sinus rhythm; a phase 3b randomized controlled trial.
    Beatch GN; Mangal B
    BMC Cardiovasc Disord; 2016 May; 16():113. PubMed ID: 27233239
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 31.